Announcements Trials
Browse Landscape

Phase

Phase 2/3 2Phase 1 2Phase 3 1Phase 2 1

Status

Completed 62Recruiting 41Unknown 38Not yet recruiting 18Terminated 12Active not recruiting 9Withdrawn 6

Sponsor Class

OTHER 6INDUSTRY 2NIH 1

Study Type

Interventional 6

Sponsor

Cancer Type

Gastrointestinal 6

Conditions

Carcinoma, Hepatocellular 3Pancreatic Neoplasms 1Colorectal Neoplasms 1Colorectal Cancer Metastatic 1

Interventions

Radiotherapy 91pembrolizumab 88Cyclophosphamide 84Gemcitabine 70Cisplatin 70Magnetic Resonance Spectroscopy 65Carboplatin 60Radiosurgery 55Paclitaxel 55Nivolumab 48Dexamethasone 45Bevacizumab 42Biopsy 41Fluorouracil 39durvalumab 37Surveys and Questionnaires 36Docetaxel 36fludarabine 35Doxorubicin 35Radiation 33Oxaliplatin 33Capecitabine 33Rituximab 32fludarabine phosphate 31Leucovorin 31Cytarabine 30Melphalan 29Etoposide 28Pemetrexed 27Irinotecan 27

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

6 trials
RecentStart dateEnrollment
Withdrawn × OTHER × Folfox protocol × Clear all
NCT03760614 2021-01-15

A Study of Entinostat and FOLFOX in Subjects With Pancreatic Adenocarcinoma

Abramson Cancer Center at Penn Medicine

Phase 1 Withdrawn
Gastrointestinal

Pancreatic Neoplasms

NCT03982121 2020-02-17

ISILI

Gustave Roussy, Cancer Campus, Grand Paris

Phase 1 Withdrawn
Gastrointestinal

Colorectal Cancer Metastatic

NCT02527772 2019-06-04

LD-FOX4/HCC

Guangxi Medical University

Phase 2/3 Withdrawn
Gastrointestinal

Carcinoma, Hepatocellular

NCT02534337 2019-06-04

Gemcitabine Plus Oxaliplatin Versus Oxaliplatin Plus Fluorouracil/Leucovorin for Hepatocellular Carcinoma

Guangxi Medical University

Phase 2/3 Withdrawn
Gastrointestinal

Carcinoma, Hepatocellular

NCT03803254 2019-05-06

HAIC Plus Lenvatinib and PD-1 Antibody Versus HAIC Plus Lenvatinib for Advanced HCC

Sun Yat-sen University

Phase 2 Withdrawn
Gastrointestinal

Carcinoma, Hepatocellular

NCT01786538 2013-03-13

Second-line FOLFOX With or Without Regorafenib in mCRC Patients Failed to First-line Irinotecan Plus Fluoropyrimidines

Asan Medical Center

Phase 3 Withdrawn
Gastrointestinal

Colorectal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡